Table 3.
Gap | Recommendation |
---|---|
We do not know which measures could be taken to prevent VT in space. We do not know the adverse effects of potential countermeasures. |
1. Assess the role of countermeasures and potential adverse effects of those countermeasures for prevention of VT, including: a. LBNP in VT prevention during space travel and in ground-based analogues36 b. Assess effectiveness of whole-body vibration (WBV) and RVE interventions to prevent VT during spaceflight and in ground-based analogues c. Assess role of anticoagulant and antiplatelet therapy for VT prevention during spaceflight and in ground-based analogues d. Assess the role of nitric oxide (NO) precursors (nitrites and nitrates) as a way to increase NO bioavailability, induce vasodilation, and prevent inappropriate aggregation / coagulation. e. Assess role of mechanical measures (e.g., compression stockings) to reduce stasis during spaceflight and in ground-based analogues f. Assess the role of exercise (type of exercise, intensity, duration, time of the day) as a way to increase prevent muscle atrophy (and the associated decreased muscle pump), induce shear stress, improve endothelial function, prevent venous stasis, inappropriate aggregation and coagulation. |